Special Features |

Improving the Management of COPD in Women OPEN ACCESS

Christine R. Jenkins, MD; Kenneth R. Chapman, Professor; James F. Donohue, Professor; Nicolas Roche, Professor; Ioanna Tsiligianni, Doctor; MeiLan K. Han, Associate Professor
Author and Funding Information

Financial/nonfinancial dislosures

CRJ is a member of national and international advisory boards and steering committees for AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim and Novartis, and contributes to many educational programmes and symposia for government, non-government organisations and the pharmaceutical industry.

KRC has consulted (last 3 years) with AstraZeneca, Baxter, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, Grifols, Kamada, Novartis, Nycomed, Roche, and Teva; has undertaken research funded by Amgen, AstraZeneca, Baxter, Boehringer Ingelheim, CSL Behring, Forest Labs, GlaxoSmithKline, Grifols, Novartis, Roche, and Takeda; and has participated in continuing medical education activities sponsored in whole or in part by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, Merck Frosst, Novartis, Pfizer, and Takeda. He is participating in research funded by the Canadian Institutes of Health Research operating grant entitled: Canadian Cohort Obstructive Lung Disease (CanCOLD). Professor Chapman holds the GSK-CIHR Research Chair in Respiratory Health Care Delivery at the University Health Network, Toronto, Canada.

JD has served as a consultant, investigator or DSMB member for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKlinie, Novartis, Teva, and Mylan.

NR has consulted for 3M Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Sanofi, Sandoz, and Teva; has received honoraria for giving presentations in continuing medical education activities sponsored in whole or in part by Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Mundipharma, Novartis, and Teva; participates in therapeutic trials funded by Boehringer Ingelheim, Chiesi, and GlaxoSmithKline; and has received research grants from Boehringer Ingelheim, Novartis, and Pfizer.

IT has received honoraria for educational activities, speaking engagements and advisory boards from Boehringer Ingelheim, Novartis, AstraZeneca and GlaxoSmithKline. MH has consulted for GlaxoSmithKline, Boehringer Ingelheim AstraZeneca and Novartis. She has also received honoraria for giving presentations sponsored in whole or in part by Boehringer Ingelheim.

Funded by: Novartis Pharma AG (Basel, Switzerland).

The George Institute for Global Health, Sydney, Australia

Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Rm 7-451 East Wing, 399 Bathurst Street, Toronto, ON, Canada

Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA

Respiratory and Intensive Care Medicine, Cochin Hospital Group, AP-HP, EA2511 University Paris Descartes, Paris, France

University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, P.O 9700 AD, Groningen, The Netherlands

Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI, USA

Correspondence to: Professor Christine R Jenkins, MD; The George Institute for Global Health, Sydney; PO Box M201, Missenden Rd, NSW 2050, Australia; Department of Thoracic Medicine, Concord Hospital; and The University of Sydney.

Copyright 2016, . All Rights Reserved.

Chest. 2016. doi:10.1016/j.chest.2016.10.031
Text Size: A A A
Published online


Chronic obstructive pulmonary disease (COPD) is a highly debilitating disease that represents a substantial and growing health burden in women. There is increasing evidence for gender-related differences in COPD risk, progression and outcomes. However, the disease receives scant attention as a women’s health issue. Thus, a multifaceted approach is required to address COPD in women, including greater awareness, minimisation of risk and further elucidation of the gender-specific factors (biological and cultural) that affect risk, disease progression and treatment success. Here we review current literature on the topic and provide suggestions for achieving better outcomes for the millions of women with COPD worldwide.

This article is only available in the PDF format. Download the PDF




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543